Market Struggles: Novo Nordisk vs Eli Lilly

This chapter explores the recent stock decline of Novo Nordisk, prompted by disappointing earnings and increased competition from Eli Lilly in the weight loss drug market. The discussion delves into the shifting preferences among healthcare providers and investors, raising concerns about Novo Nordisk's urgent need for a strategic response to reclaim market share.